Clinical Trial Update: Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial of regorafenib in combination with pembrolizumab for MSI-H colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)
• Stivarga (regorafenib) (regorafenib)

Snippet

Sponsor: Anwaar Saeed | Conditions: MSI-H Colorectal Cancer | Phase 2 | Status: TERMINATED